The Courier Mail, The Australian | ‘Brisbane drug company gets the rise on Viagra’
News Corp (The Courier Mail, The Australian) Business Journalist, Glen Norris, has published an article in today’s business section titled ‘Brisbane drug company gets the rise on Viagra’. It examines the PDE5 inhibitor market and why SPONTAN® may be a preferred treatment, as a potentially fast-acting intranasal spray solution. Click here to read the full […]
Ausbiz | LTR Pharma ASX Debut
LTR Pharma (ASX:LTP) Independent Non-Executive Director, Dr Julian Chick, was interviewed on Ausbiz to discuss the Company’s ASX debut. Take a look:
Biotech Daily | 11 December 2023
LTR Pharma has again been featured in Biotech Daily in an article titled, ‘LTR Up 105% On Spontan Erectile Dysfunction IPO’. Read the full report.
Stockhead | ‘Huge IPO interest and not lithium? LTR Pharma could be the next big thing on the ASX’
Stockhead journalist, Rob Badman, has reported on the upcoming LTR Pharma IPO today in an article title ‘Huge IPO interest and not lithium? LTR Pharma could be the next big thing on the ASX’. Featuring highlights from a 1:1 interview with Alpine Capital‘s Co-Founder and Head of Institutional Sales, Phil Cawood, the article covers interesting […]
Biotech Daily | 17 Nov 2023
LTR Pharma has been featured in Biotech Daily. The article discusses the potential for the Company to disrupt the Erectile Dysfunction (ED) market with its commercialisation plans for intra-nasal product, SPONTAN®. The article also showcases the expertise of the team at LTR Pharma, writing: “The company said its Mr Rodne was the former chief executive […]